As methylation levels in the NCAPH2/LMF2 gene promoter region were decreased in both the aMCI and AD groups, this marker may reflect some kind of degenerative process in the brain, but not the clinical onset of AD. The gene discussed is LMF2; the disease is Alzheimer disease.